Posted by Michael Wonder on 22 Feb 2018
Minutes from November 2017 PTAC meeting provide interesting insights on Roche's submission for Kadcyla
21 February 2018 - The minutes need to be read carefully as they start with a subcommittee outcome.
The Subcommittee recommended that trastuzumab emtansine be funded with low priority for second-line treatment of patients with HER-2 positive metastatic breast cancer who have previously received trastuzumab and a taxane.
The Committee recommended that the application be referred to the Cancer Treatments Subcommittee for advice regarding the likely benefit for patients previously treated with pertuzumab, impact on quality of life, appropriate place and sequence in New Zealand treatment settings, estimated patient numbers, and proposed access criteria.
This was Roche's first submission to PHARMAC for Kadcyla which has been considered (and eventually recommended for funding) by other HTA agencies around the world.
